AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32573166 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral plasty enhancement (Group A)
Number of subjects: 18
Study 32573166 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral plasty enhancement (Group B)
Number of subjects: 18
Study 32573166 — intervention group
Group type: COMPARATOR
Intervention: Control group (corresponding contralateral specimens)
Number of subjects: 18
Study 34427849 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual care based on the Sound Heart Model; 8 individual counseling sessions, 15-45 minutes each, face-to-face during dialysis, once a week
Number of subjects: 0
Study 34427849 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 32901441 — intervention group
Group type: EXPERIMENTAL
Intervention: New template
Number of subjects: 36
Study 32901441 — intervention group
Group type: COMPARATOR
Intervention: Standard template
Number of subjects: 36
Study 34490822 — intervention group
Group type: EXPERIMENTAL
Intervention: 11+ Injury Prevention Program (IPP)
Number of subjects: 100
Study 33208826 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (BMI ≥ 30 kg/m2)
Number of subjects: 87
Study 33208826 — intervention group
Group type: EXPERIMENTAL
Intervention: Class III obesity
Number of subjects: 87
Study 34910161 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT with FOS-enriched inulin (12 g·d‐1)
Number of subjects: 40
Study 34910161 — intervention group
Group type: COMPARATOR
Intervention: HIIT with maltodextrin/placebo
Number of subjects: 40
Study 34547069 — intervention group
Group type: EXPERIMENTAL
Intervention: Air polishing with erythritol powder before ultrasonic scaling (Group A)
Number of subjects: 10
Study 34547069 — intervention group
Group type: EXPERIMENTAL
Intervention: Air polishing with erythritol powder after ultrasonic scaling (Group B)
Number of subjects: 10
Study 34547069 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Group A and Group B
Number of subjects: 10
Study 33784438 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal nutritional supplements
Number of subjects: 467
Study 32609230 — intervention group
Group type: EXPERIMENTAL
Intervention: MI Paste (MP)
Number of subjects: 10
Study 32609230 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride dentifrice (FD)
Number of subjects: 10
Study 32609230 — intervention group
Group type: EXPERIMENTAL
Intervention: MI Paste Plus (MPP)
Number of subjects: 10
Study 32609230 — intervention group
Group type: COMPARATOR
Intervention: Silica dentifrice without fluoride (CO)
Number of subjects: 10
Study 34371872 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide formula (PF) 1.5 kcal/mL
Number of subjects: 26
Study 34371872 — intervention group
Group type: COMPARATOR
Intervention: Standard intact protein formula (SF)
Number of subjects: 26
Study 33162512 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA + ATO
Number of subjects: 0
Study 33162512 — intervention group
Group type: COMPARATOR
Intervention: ATRA + chemotherapy
Number of subjects: 0
Study 34403141 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of intravenous squalene twice a day and standard treatment for 6 days
Number of subjects: 30
Study 34403141 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 30
Study 33949762 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother Matters (intervention)
Number of subjects: 98
Study 33949762 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 98
Study 35488787 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine (0.3 mg/kg) combined with propofol
Number of subjects: 102
Study 35488787 — intervention group
Group type: COMPARATOR
Intervention: Dezocine (0.05 mg/kg) combined with propofol
Number of subjects: 102
Study 32997817 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT) associated with Preventive Oral Care Program (POCP)
Number of subjects: 48
Study 32997817 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT)
Number of subjects: 48
Study 32997817 — intervention group
Group type: COMPARATOR
Intervention: Control (POCP only)
Number of subjects: 48
Study 33739022 — intervention group
Group type: EXPERIMENTAL
Intervention: Nolasiban 900 mg
Number of subjects: 45
Study 33739022 — intervention group
Group type: EXPERIMENTAL
Intervention: Nolasiban 1800 mg
Number of subjects: 45
Study 33739022 — intervention group
Group type: EXPERIMENTAL
Intervention: Nolasiban (both dosages)
Number of subjects: 45
Study 33739022 — intervention group
Group type: COMPARATOR
Intervention: Meal consumption (control for QTc assessment)
Number of subjects: 45
Study 33739022 — intervention group
Group type: COMPARATOR
Intervention: Sex hormones (independent assessment)
Number of subjects: 45
Study 34460345 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver strain measurement using validated tools
Number of subjects: 851
Study 34460345 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with caregiver strain
Number of subjects: 851
Study 32020824 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (0.04% tretinoin microspheres + 1% clindamycin)
Number of subjects: 750
Study 32020824 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (0.025% tretinoin)
Number of subjects: 750
Study 32020824 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (1% clindamycin)
Number of subjects: 750
Study 35041627 — intervention group
Group type: COMPARATOR
Intervention: Clear fluids only (prep 1)
Number of subjects: 834
Study 35041627 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard regimen plus 500 mL PEG after SBCE ingestion (prep 2)
Number of subjects: 834
Study 35041627 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard regimen plus 2 L PEG plus 500 mL PEG after SBCE ingestion (prep 3)
Number of subjects: 834
Study 35041627 — intervention group
Group type: EXPERIMENTAL
Intervention: Prep 2 and 3 groups
Number of subjects: 834
Study 35041627 — intervention group
Group type: EXPERIMENTAL
Intervention: Prep 2 group
Number of subjects: 834
Study 33373286 — intervention group
Group type: EXPERIMENTAL
Intervention: Spray-inoculated with a suspension of conidia (1×10^5 spores/ml) for 7 days
Number of subjects: 18
Study 33373286 — intervention group
Group type: COMPARATOR
Intervention: Sterile water (control)
Number of subjects: 18
Study 35615776 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural interventions (including text messages)
Number of subjects: 13
Study 32204957 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher years of schooling
Number of subjects: 45
Study 32204957 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher urate levels
Number of subjects: 45
Study 36152778 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alcohol (target level: 0.05 g%)
Number of subjects: 0
Study 36152778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35645071 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser (970 ± 15 nm)
Number of subjects: 45
Study 35645071 — intervention group
Group type: COMPARATOR
Intervention: Saline irrigation
Number of subjects: 45
Study 36219172 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-minute withdrawal time (9MF)
Number of subjects: 733
Study 33383230 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind (tablet‐based cognitive training)
Number of subjects: 254
Study 33383230 — intervention group
Group type: EXPERIMENTAL
Intervention: Move (lifestyle physical activity with goal‐setting and group meetings)
Number of subjects: 254
Study 33383230 — intervention group
Group type: EXPERIMENTAL
Intervention: MindMoves (combined intervention of Mind and Move)
Number of subjects: 254
Study 33383230 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 254
Study 33383230 — intervention group
Group type: EXPERIMENTAL
Intervention: MindMoves
Number of subjects: 254
Study 35389906 — intervention group
Group type: EXPERIMENTAL
Intervention: Core decompression (CD) with bone marrow aspiration concentrate (BMAC)
Number of subjects: 40
Study 35389906 — intervention group
Group type: COMPARATOR
Intervention: Core decompression (CD) alone
Number of subjects: 40
Study 35389906 — intervention group
Group type: COMPARATOR
Intervention: Core decompression (CD) with polymethylmethacrylate cement (PMMA)
Number of subjects: 40
Study 34348526 — intervention group
Group type: EXPERIMENTAL
Intervention: Drospirenone 4 mg
Number of subjects: 1190
Study 34348526 — intervention group
Group type: COMPARATOR
Intervention: Desogestrel 75 µg
Number of subjects: 1190
Study 32416442 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle exercise (IME) at 60% maximal inspiratory pressure (PImax)
Number of subjects: 14
Study 32416442 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle exercise (IME) at 2% maximal inspiratory pressure (PImax)
Number of subjects: 14
Study 32416442 — intervention group
Group type: COMPARATOR
Intervention: Inspiratory muscle exercise (IME) at 60% PImax
Number of subjects: 14
Study 34989404 — intervention group
Group type: EXPERIMENTAL
Intervention: Amaka-parents intervention
Number of subjects: 636
Study 34989404 — intervention group
Group type: EXPERIMENTAL
Intervention: Amaka-community intervention
Number of subjects: 636
Study 34989404 — intervention group
Group type: COMPARATOR
Intervention: Control condition (usual care)
Number of subjects: 636
Study 33137403 — intervention group
Group type: EXPERIMENTAL
Intervention: Duck circovirus (DuCV) infection
Number of subjects: 69
Study 33137403 — intervention group
Group type: EXPERIMENTAL
Intervention: DuCV strains AHAU9, AHAU25, AHAU28, AHAU37, and AHAUHQ
Number of subjects: 69
Study 33137403 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombination analysis of DuCV-1d subtype strains
Number of subjects: 69
Study 32664877 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinepazide maleate injection (320 mg, intravenous infusion, once daily for 14 days)
Number of subjects: 937
Study 32664877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 937
Study 35490210 — intervention group
Group type: EXPERIMENTAL
Intervention: Visser reference curve
Number of subjects: 12953
Study 35490210 — intervention group
Group type: EXPERIMENTAL
Intervention: Hoftiezer chart
Number of subjects: 12953
Study 35490210 — intervention group
Group type: EXPERIMENTAL
Intervention: INTERGROWTH chart
Number of subjects: 12953
Study 35490210 — intervention group
Group type: COMPARATOR
Intervention: All three charts
Number of subjects: 12953
Study 32442258 — intervention group
Group type: EXPERIMENTAL
Intervention: SAVR
Number of subjects: 223
Study 32442258 — intervention group
Group type: COMPARATOR
Intervention: TAVR
Number of subjects: 223
Study 33468249 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate (GS; 1500 mg) and bovine chondroitin sulfate (CS; 1200 mg)
Number of subjects: 627
Study 33468249 — intervention group
Group type: COMPARATOR
Intervention: Reference product (RP)
Number of subjects: 627
Study 35842711 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac patients (n = 139)
Number of subjects: 139
Study 35842711 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG group
Number of subjects: 139
Study 36281090 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up by clinical pharmacists
Number of subjects: 120
Study 36281090 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 120
Study 33026719 — intervention group
Group type: EXPERIMENTAL
Intervention: Naphazoline Hydrochloride
Number of subjects: 72
Study 33026719 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum Chloride
Number of subjects: 72
Study 33026719 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study 32385307 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium cut-off (MCO) dialyzer (Theranova 400, Baxter)
Number of subjects: 49
Study 33911186 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoiesis stimulating agents (ESAs)
Number of subjects: 80
Study 33911186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 33911186 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusions
Number of subjects: 80
Study 32317700 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck-specific exercise (NSE)
Number of subjects: 171
Study 32317700 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck-specific exercise with a behavioural approach (NSEB)
Number of subjects: 171
Study 32317700 — intervention group
Group type: COMPARATOR
Intervention: Physical activity prescription (PPA)
Number of subjects: 171
Study 33485309 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (personalised cancer risk information and tailored behaviour change advice)
Number of subjects: 62
Study 33485309 — intervention group
Group type: COMPARATOR
Intervention: Standard NHS Health Check
Number of subjects: 62
Study 33485309 — intervention group
Group type: COMPARATOR
Intervention: Standard chronic disease review
Number of subjects: 62
Study 33485309 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic disease review plus intervention
Number of subjects: 62
Study 34889733 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiroxostat 200 mg
Number of subjects: 733
Study 34889733 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiroxostat 80 mg
Number of subjects: 733
Study 34889733 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 200 mg
Number of subjects: 733
Study 34889733 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiroxostat 120 mg
Number of subjects: 733
Study 34889733 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiroxostat 160 mg
Number of subjects: 733
Study 34889733 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiroxostat 60 mg
Number of subjects: 733
Study 34889733 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiroxostat 40 mg
Number of subjects: 733
Study 34889733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 733
Study 32503473 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention for 12 months, 3 days/week
Number of subjects: 0
Study 32503473 — intervention group
Group type: COMPARATOR
Intervention: Control group maintaining normal lifestyle
Number of subjects: 0
Study 32503473 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention
Number of subjects: 0
Study 34371933 — intervention group
Group type: EXPERIMENTAL
Intervention: Early dinner (at 18:00)
Number of subjects: 12
Study 34371933 — intervention group
Group type: COMPARATOR
Intervention: Late dinner (at 21:00)
Number of subjects: 12
Study 32631211 — intervention group
Group type: COMPARATOR
Intervention: Minimal Intervention (one-session, information-only, group-delivered)
Number of subjects: 0
Study 32631211 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Intervention (two-session, group-delivered)
Number of subjects: 0
Study 35450451 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized nursing management program
Number of subjects: 140
Study 35450451 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care (control)
Number of subjects: 140
Study 32776237 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterweight-Plus weight management programme
Number of subjects: 0
Study 32776237 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 0
Study 36256949 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (1,000 IU cholecalciferol/d)
Number of subjects: 160
Study 36256949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 34397820 — intervention group
Group type: EXPERIMENTAL
Intervention: Oolong tea (O‐)
Number of subjects: 395
Study 34397820 — intervention group
Group type: EXPERIMENTAL
Intervention: High concentration simethicone solution (S2‐)
Number of subjects: 395
Study 34397820 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (D‐)
Number of subjects: 395
Study 34397820 — intervention group
Group type: EXPERIMENTAL
Intervention: Low concentration simethicone solution (S1‐)
Number of subjects: 395
Study 32941395 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC) Cmin of 4-7 ng/mL
Number of subjects: 904
Study 32941395 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC) Cmin of 4-7 ng/mL after propensity score matching
Number of subjects: 904
Study 32941395 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (TAC) Cmin of 7-10 ng/mL
Number of subjects: 904
Study 32941395 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (TAC) Cmin of >10 ng/mL
Number of subjects: 904
Study 35924472 — intervention group
Group type: EXPERIMENTAL
Intervention: ME group (ablation using mini-electrode catheters)
Number of subjects: 136
Study 35924472 — intervention group
Group type: COMPARATOR
Intervention: Control group (ablation using conventional catheters)
Number of subjects: 136
Study 34191033 — intervention group
Group type: EXPERIMENTAL
Intervention: NAD+-precursor supplementation (207.5 mg niacin equivalents/day) for 32 days
Number of subjects: 14
Study 34191033 — intervention group
Group type: EXPERIMENTAL
Intervention: NAD+-precursor supplementation
Number of subjects: 14
Study 32435772 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with chitosan nanoparticles (Csnp) solution under ultrasonic agitation for 60 s and immersed in EDC crosslinker for 24 h
Number of subjects: 48
Study 32435772 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersion in 2.5% glutaraldehyde for 24 h
Number of subjects: 48
Study 32435772 — intervention group
Group type: COMPARATOR
Intervention: Control group (without treatment)
Number of subjects: 48
Study 35219335 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ankle exoskeletons
Number of subjects: 10
Study 34444843 — intervention group
Group type: EXPERIMENTAL
Intervention: Arabinoxylan (AX)
Number of subjects: 239
Study 34444843 — intervention group
Group type: COMPARATOR
Intervention: Control (CTRL)
Number of subjects: 239
Study 32522244 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime 400 mg orally two times per day for 10 days (n = 140)
Number of subjects: 210
Study 32522244 — intervention group
Group type: COMPARATOR
Intervention: Benzathine penicillin G 2.4 million units intramuscularly based on the stage of syphilis infection (n = 70)
Number of subjects: 210
Study 36445170 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth training group (TR) - systematic physical and cognitive exercises, 50-min sessions, three times a week for 12 weeks
Number of subjects: 78
Study 36445170 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - non-systematized guidance for 12 weeks
Number of subjects: 78
Study 32977975 — intervention group
Group type: EXPERIMENTAL
Intervention: As-needed acetaminophen + codeine
Number of subjects: 126
Study 32977975 — intervention group
Group type: COMPARATOR
Intervention: Scheduled acetaminophen/as-needed tramadol
Number of subjects: 126
Study 32977975 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 126
Study 33019274 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartwatch group (intervention)
Number of subjects: 120
Study 33019274 — intervention group
Group type: COMPARATOR
Intervention: Handwashing group (control)
Number of subjects: 120
Study 35784564 — intervention group
Group type: EXPERIMENTAL
Intervention: MMI combined with Se and VitD
Number of subjects: 42
Study 35784564 — intervention group
Group type: COMPARATOR
Intervention: MMI monotherapy
Number of subjects: 42
Study 34627265 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple stent (MS) group
Number of subjects: 168
Study 35123569 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-supported mindfulness-based cognitive therapy (MBCT) for 8 weeks with weekly group sessions via videoconference, asynchronous homework, an online retreat after the fifth week, and 4 monthly booster sessions after completion of the 8-week programme.
Number of subjects: 111
Study 35123569 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 111
Study 33314545 — intervention group
Group type: EXPERIMENTAL
Intervention: Real continuous theta-burst stimulation (cTBS) on the left supplementary motor area (SMA) for 14 consecutive days
Number of subjects: 42
Study 33314545 — intervention group
Group type: COMPARATOR
Intervention: Sham continuous theta-burst stimulation (cTBS)
Number of subjects: 42
Study 33068295 — intervention group
Group type: EXPERIMENTAL
Intervention: CFC-health questionnaire
Number of subjects: 1001
Study 33068295 — intervention group
Group type: COMPARATOR
Intervention: CFC-general questionnaire
Number of subjects: 1001
Study 33068295 — intervention group
Group type: EXPERIMENTAL
Intervention: CFC-I and CFC-F dimensions
Number of subjects: 1001
Study 33068295 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-evaluated health behaviors
Number of subjects: 1001
Study 35725576 — intervention group
Group type: EXPERIMENTAL
Intervention: C-PPRS (Chinese version of the Perceived Partner Responsiveness Scale)
Number of subjects: 441
Study 35725576 — intervention group
Group type: EXPERIMENTAL
Intervention: C-PPRS
Number of subjects: 441
Study 34139272 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab with carboplatin, paclitaxel, and bevacizumab
Number of subjects: 550
Study 34139272 — intervention group
Group type: COMPARATOR
Intervention: Placebo with carboplatin, paclitaxel, and bevacizumab
Number of subjects: 550
Study 35868146 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly LAGH (0.7 mg/kg/week)
Number of subjects: 10
Study 35868146 — intervention group
Group type: COMPARATOR
Intervention: Daily GH (0.37 mg/kg/week)
Number of subjects: 10
Study 32645310 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of mitomycin C (MMC)
Number of subjects: 100
Study 32645310 — intervention group
Group type: COMPARATOR
Intervention: Direct scleral application of mitomycin C (MMC)
Number of subjects: 100
Study 33108247 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Adherence Report Scale (MARS)
Number of subjects: 0
Study 33108247 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmatory factor analysis (CFA) of MARS
Number of subjects: 0
Study 33108247 — intervention group
Group type: EXPERIMENTAL
Intervention: MARS compared with caregiver-reported medication adherence
Number of subjects: 0
Study 33108247 — intervention group
Group type: EXPERIMENTAL
Intervention: MARS compared with Asthma Medication Ratio (AMR), asthma control, and caregiver perception of asthma control
Number of subjects: 0
Study 35320964 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal 3 mg hyperbaric bupivacaine 0.5% plus 20 microgram fentanyl and intravenous fentanyl at 1μg.kg(‐1).h(‐1)
Number of subjects: 100